Viridian Therapeutics, Inc.DE - Common Stock, $0.01 par value per share (VRDN)

Historical Holders from Q4 2020 to Q1 2025

Symbol
VRDN on Nasdaq
CUSIP
92790C104
Type / Class
Equity / Common Stock, $0.01 par value per share
Shares outstanding
81.1M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
91M
Holdings value
$1.75B
% of all portfolios
0.006%
Grand Portfolio weight change
+0%
Number of holders
178
Number of buys
107
Number of sells
-65
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.002%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Viridian Therapeutics, Inc.DE - Common Stock, $0.01 par value per share (VRDN)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
COMMODORE CAPITAL LP 5.3% $58M 4.3M Commodore Capital LP Apr 4, 2025
Venrock Healthcare Capital Partners III, L.P. 4.5% $48.2M 3.58M Venrock Healthcare Capital Partners III, L.P. Dec 31, 2024

Institutional Holders of Viridian Therapeutics, Inc.DE - Common Stock, $0.01 par value per share (VRDN)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 363K $4.89M -$76K $13.48 11
2024 Q4 91M $1.75B +$57.7M $19.17 178
2024 Q3 86.9M $1.98B +$415M $22.75 165
2024 Q2 69.5M $904M -$23.1M $13.01 137
2024 Q1 71M $1.24B +$176M $17.51 135
2023 Q4 60.1M $1.31B +$175M $21.78 130
2023 Q3 50.2M $770M +$30.5M $15.34 122
2023 Q2 47.1M $1.12B +$92.6M $23.79 127
2023 Q1 43.1M $1.1B +$41M $25.44 134
2022 Q4 40.9M $1.19B +$88.2M $29.21 119
2022 Q3 37.8M $775M +$210M $20.51 101
2022 Q2 28.2M $327M +$27.4M $11.57 76
2022 Q1 24.9M $461M +$26.5M $18.49 71
2021 Q4 23.3M $460M +$113M $19.77 52
2021 Q3 13.6M $224M +$123M $16.45 38
2021 Q2 6M $110M +$18.4M $18.29 24
2021 Q1 5.09M $84.5M +$80.7M $16.71 29
2020 Q4 229K $3.77M +$3.77M $16.46 2